Phase I taselisib results and a cell-free DNA assay

Bookmark and Share
Published: 25 Apr 2018
Views: 4098
Rating:
Save
Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Baselga speaks with ecancer at AACR 2018 about results from a phase I basket study of taselisib to treat locally advanced or metastatic solid tumours harbouring a PIK3CA mutation.

He highlights how these mutations occur in a host of sites throughout the body.

Dr Baslega also describes results from the development of a cell-free DNA assay, allowing for early detection and monitoring treatment response.